Premium
Phase 1b study of XPro1595 in Alzheimer's patients with biomarkers of inflammation
Author(s) -
Barnum Christopher,
Tesi Raymond,
Malberg Jessica
Publication year - 2021
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1002/alz.057872
Subject(s) - neuroinflammation , inflammation , white matter , neuroimaging , neurodegeneration , medicine , biomarker , neuroscience , pathology , psychology , magnetic resonance imaging , biology , disease , radiology , biochemistry
Background XPro1595 is currently being tested in a proof of biology Phase 1b study in Alzheimer’s patients with biomarkers of inflammation. Method Inflammatory and neurodegeneration protein and imaging biomarkers were measured 3 months after weekly treatment with multiple doses of XPro1595. Result XPro1595 dose‐dependently reduced All CSF inflammatory protein levels and neuroimaging inflammatory markers (free water white matter). Moreover, we observed a strong correlation between MRI inflammation (Free water white matter) and CSF inflammation was observed (R 2 =0.761). In addition to the reduction in neuroinflammation, XPro1595 reduced biomarkers of neural injury and synaptic dysfunction as assessed by CSF protein and neuroimaging. Additional data on novel MRI metrics to assess neuroinflammation and white/gray matter quality will be presented. Conclusion XPro1595 achieved its primary goal of reduced markers of neuroinflammation, neural injury, synaptic dysfunction across multiple measures and assays. Data support advancement to Phase 2.